Up to $2.64 Billion: Pfizer and Starry Pharmaceutical Sign In Vivo CAR-T Licensing Agreement
1 day ago / Read about 0 minute
Author:小编   

Pfizer and Starry Pharmaceutical have entered into an exclusive licensing agreement under which Pfizer gains exclusive rights to develop, manufacture, and commercialize three pre-IND in vivo CAR-T programs in the autoimmune disease field outside Greater China. Pfizer may also leverage Starry Pharmaceutical's proprietary in vivo CAR-T technology to conduct research in inflammatory and immune diseases and oncology, and holds the option to secure exclusive licensing of candidate compounds arising from the collaborative research or to expand the licensed territory to include Greater China. Starry Pharmaceutical will receive an upfront payment of $330 million, milestone payments of up to $2.3 billion, and tiered royalties on net sales of approved products. Founded in 2021, Starry Pharmaceutical focuses on extrahepatic targeted delivery technology and has built independently owned mRNA and targeted LNP technology platforms, with a pipeline spanning multiple therapeutic areas. In May 2026, the company completed a Series B+ financing round of nearly $40 million.